Novartis
1Q Revenues: $11.1 billion (+2%)
1Q Earnings: $1.8 billion (-13%)
Comments: Growth was driven by Cosentyx ($791 million, +36%), Entresto ($357 million, +79%), Lutathera (sales of $106 million), Promacta ($307 million, +19%) and Kisqali (sales of $91 million), partly offset by the negative impacts of pricing and generic competition. Tasigna sales were down 7% to $434 million. Sandostatin sales were down 2% to $392 million. Gleevec sales were down 22% to $307 million. Exjade sales were down 9% to 238 million. Votrient sales were down 13% to $187 million. Gilenya sales were $766 million, down 7%, as volume growth in EU was offset by a decline in U.S. due to competitive pressures. Lucentis sales were $533 million, up 2%.